Oncotelic Therapeutics ( (OTLC) ) has released a notification of late filing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncotelic Therapeutics, Inc. has filed a Form 12b-25, indicating a delay in submitting its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the company’s inability to compile the necessary financial information without incurring unreasonable effort or expense. Oncotelic Therapeutics anticipates filing the report within the extension period allowed by the SEC, which is the fifteenth calendar day following the prescribed due date. The company does not expect any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Amit Shah, the Chief Financial Officer, who assured ongoing compliance efforts.
More about Oncotelic Therapeutics
YTD Price Performance: 100%
Average Trading Volume: 147,629
Technical Sentiment Signal: Sell
Current Market Cap: $28.02M
Learn more about OTLC stock on TipRanks’ Stock Analysis page.